Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
20 patients around the world
Available in Mexico
Patientes with Refractory/relapsed Hodgkin Lymphoma (HL R/R) with multiple failed
therapies represent a therapeutic dilemma. The goal of next-line treatment is long-term
disease control with manageable adverse reactions. Given the limited therapeutic options
for patients with HL R/R, better therapies should be sought, more effective, with better
tolerability, less toxicity, with increased overall survival (OS) of the patients, with
the aim of improving outcomes in terms of disease-free survival progression (PFS) of the
current standard treatment. Since currently only 50% of the patients with high-risk R/R
HL treated with the standard regimen achieve healing. The high effectiveness and low
toxicity of immunotherapy with prolonged remission or stabilization of the disease make
it a new treatment option promising for HL R/R. Based on the above, a treatment strategy
is proposed to rescue base with Brentuximab plus PD-1 blockade followed by
autotransplantation and consolidation with Brentuximab plus PD-1 blockade in patients
with Hodgkin lymphoma High-Risk Relapse/Refractory Compared to Reported OS and PFS Rates
in the literature obtained with standard treatment.
Hospital Regional de Alta Especialidad del Bajio
1Research sites
20Patients around the world
This study is for people with
Lymphoma
Hodgkin lymphoma
Requirements for the patient
To 90 Years
All Gender
Medical requirements
Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
Age ≥ 18 years and ≤ 90 years.
ECOG performance status ≤ 3
Women of reproductive potential should have a serum pregnancy test or negative urine.
Prior signature of the informed consent.
Adequate liver function, defined as:
- Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
- Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
Adequate renal functions, defined as:
• Serum creatinine ≤ 1.5x ULN or glomerular filtration rate > 50ml/min.
Voluntary withdrawal from the study.
Develop grade 3 or 4 toxicity according to the INH scale.
Loss of follow-up
Sites
Hospital Regional de Alta Especialidad del Bajío
Recruiting
Blvd. Milenio, Fracciones de los Aguirre, 37544 León de los Aldama, Gto., Mexico
StudyAdcetris
SponsorHospital Regional de Alta Especialidad del Bajio